Regulatory Post Marketing Surveillance Study on Nexavar

Trial Profile

Regulatory Post Marketing Surveillance Study on Nexavar

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Apr 2015 Planned End Date changed from 1 Jun 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
    • 24 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top